 relationship chemotherapeut endocrin intervent natur killer cell activ human breast cancer peripher natur killer NK activ target tumor cell patient breast cancer treatment combin chemotherapi and/or endocrin therapi NK activ untreat stage patient evid diseas healthi control NK activ individu cytotox drug therapi reduct lymphocyt recoveri chemotherapeut intervent lymphocyt count calcul absolut NK activ signific reduct NK activ patient local system diseas chemotherapi differ chemotherapeut agent NK activ stage II patient phenylalanin mustard PF cyclophosphamid /methotrex cmf show signific reduct overal NK activ rel healthi control stage patient ned patient p/doxorubicin /f/tamoxifen Tx paft reduc NK activ rel patient patient short-dos c/a CA protocol normal level overal NK activ high-risk stage patient methotrex /F MF sequenti leucovorin rescu patient metastat diseas endocrin therapi Tx acet meg overal NK activ rang healthi control patient system diseas cmf cmf/vincristine/prednison cmfvp vinblastine/a/thiotepa/fluoxymesteron vath mitomycin/mitoxantron mtmx regimen overal level absolut NK healthi control metastat patient endocrin therapi NK cytolyt data multipl effector ratio exponenti regress analysi elev NK cell respons stage patient ned declin NK cell respons cytotox chemotherapi due alter maxim plateau level NK cell cytotox asymptot valu valu regress analysi indic rel kill capac individu NK cell unalt popul result cytolyt lymphocyt NK pool stage patient cancer result cytotox therapi